Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 6/20 | 0.34 |
| ▸ | GAA | P10253 | 5/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.34 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | SNCA | P37840 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590797 | 0.96 | PDK2 (0.46) | PDK2GABRA1GABRB2MAPTMEN1 | |
| Iodide SCHEMBL9932003 | 0.93 | PDK2 (0.39) | PDK2GABRA1GABRB2MAPTMEN1 | |
| SCHEMBL2592493 | 0.89 | PDK2 (0.41) | PDK2GABRA1GABRB2MAPTMEN1 | |
| Iodide SCHEMBL2593575 | 0.87 | PDK2 (0.36) | PDK2GABRA1GABRB2MAPTMEN1 | |
| SCHEMBL2582870 | 0.84 | NOX1 (0.53) | PDK2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL9932940 | 0.83 | PDK2 (0.37) | PDK2GABRA1GABRB2MAPTMEN1 | |
| SCHEMBL15925823 | 0.77 | MAPT (0.46) | PDK2MAPTMEN1KMT2ATDP1 | |
| Iodide SCHEMBL12828778 | 0.75 | PDK2 (0.32) | PDK2 | |
| SCHEMBL12273283 | 0.74 | PRMT6 (0.35) | PDK2MAPTMEN1KMT2ATDP1 | |
| SCHEMBL15926398 | 0.73 | NOX1 (0.36) | PDK2MAPTMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699241-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-2585073-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8828986-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8809317-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8785434-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8759336-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2699241-A1 | ANTIVIRAL COMPOUNDS | Prosetta Antiviral Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-2585073-A1 | ANTIVIRAL COMPOUNDS | Prostetta Antiviral Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120302556-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012145567-A1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270854-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012135402-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120238543-A1 | Antiviral Compounds | Prosetta Antiviral, Inc. (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012125983-A1 | ANTIVIRAL TREATMENTS | PROSETTA ANTIVIRAL INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120157435-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011137447-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238543-A1 | Antiviral Compounds | MAVS, EIF2AK2, IRF3 | ACHE 898/4885PDK2 2296/4885GABRA1 4470/4885 |
| US-20120157435-A1 | Antiviral Compounds | MAVS, ZC3HAV1, EIF2AK2 | ACHE 1024/4885PDK2 1288/4885GABRA1 2007/4885 |
| US-20120270854-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | ACHE 737/4885PDK2 1701/4885GABRA1 2108/4885 |
| US-20120302556-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | ACHE 737/4885PDK2 1701/4885GABRA1 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.